Skip to main content
editorial
. 2019 Mar 1;10(18):1664–1666. doi: 10.18632/oncotarget.26752

Figure 1. Genomic alterations identified in brain tumors and potential therapeutic agents.

Figure 1

The agents shown here have been tested in various cancer types and the highest stage of clinical trials or FDA approval for any type of tumor is indicated. Only PLB-1001 has been examined specifically in glioblastoma patients. Additional clinical studies are needed to assess the efficacy of many of these agents in the brain. $ For BRAF V600E mutants. No current FDA-approved therapy for RAF fusions. # RAF drugs which block RAF dimerization are likely to act on fusions but clinical activity not published to date. ^Breakthrough designation indicates FDA signal to expedite the development given promising preliminary signs of clinical efficacy.